Lombardy has emerged as the top center for pharmaceutical manufacturing in Europe, surpassing competitors such as Île de France and Dublin in the small molecule category.
Lombardy's success in pharmaceutical manufacturing can be attributed to several key factors:
Lombardy is also becoming a leading hub for Active Pharmaceutical Ingredient (API) production, rivaling Germany.
Milan, in particular, has established itself as a prominent location for contract manufacturing of advanced biologics and pharmaceuticals, attracting global investment.
The upcoming CPHI Milan event is expected to bring in a large number of visitors and inject millions of euros into the local economy.
Lombardy's future in pharmaceutical manufacturing looks promising, with industry leaders recognizing its potential for establishing new small molecule sites and expanding bioproduction capabilities.
The region's emphasis on research and development, safety, health, and environmental standards further enhances its pharmaceutical capabilities.
Lombardy aims to reduce dependency on markets in China and India by leveraging national resources and Italian quality.
Overall, Lombardy's recognition as the premier center for pharmaceutical manufacturing in Europe reflects its well-established ecosystem that promotes innovation, investment, and growth.